Nauru CDS

Thrombolysis & Anticoagulation Protocols

Comprehensive protocols for thrombolytic agents and anticoagulants with weight-based dosing and monitoring

Agents
Tenecteplase (TNKase)
Fibrin-specific thrombolytic
1A

Indication

Acute ST-elevation myocardial infarction (STEMI), acute pulmonary embolism, acute ischemic stroke (within 4.5 hours)

Preparation

Reconstitute with provided diluent. Use immediately after reconstitution.

Clinical Notes

  • Fibrin-specific - less systemic fibrinolysis than non-selective agents
  • Single bolus - easier administration than alteplase
  • Preferred agent in STEMI (ASSENT-2 trial)
  • Time is muscle - minimize door-to-needle time
  • Adjunctive antiplatelet therapy (aspirin, P2Y12 inhibitor) required
  • Adjunctive anticoagulation (heparin, enoxaparin) required
  • Percutaneous coronary intervention (PCI) preferred over thrombolysis if available

Evidence

Grade: 1A

  • ACC/AHA Guidelines for STEMI Management 2013
  • ASSENT-2 Trial - Lancet 1999
  • Antman EM, et al. Circulation 2004